Priscilla Velentgas

Summary

Affiliation: Harvard Medical School and Harvard Pilgrim Health Care
Country: USA

Publications

  1. doi request reprint A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study
    Priscilla Velentgas
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Pharmacoepidemiol Drug Saf 17:1226-34. 2008
  2. doi request reprint Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination
    Priscilla Velentgas
    Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:1350-8. 2012

Detail Information

Publications2

  1. doi request reprint A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study
    Priscilla Velentgas
    Department of Ambulatory Care and Prevention, Harvard Medical School and Harvard Pilgrim Health Care, Boston, MA 02215, USA
    Pharmacoepidemiol Drug Saf 17:1226-34. 2008
    ..Implementation has addressed several issues relevant to creation of a large scale post-marketing drug safety surveillance system envisioned by the FDA's Sentinel Initiative...
  2. doi request reprint Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination
    Priscilla Velentgas
    Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, MA, USA
    Pharmacoepidemiol Drug Saf 21:1350-8. 2012
    ..We conducted a study to assess the risk of GBS after MCV4 vaccination using health plan administrative and claims data together with the review of primary medical records of potential cases...